Drug Approval | March 17, 2022
Lynparza reduced risk of death by 32% in the adjuvant treatment of patients with breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
The initial SARS-CoV-2 research program at Calibr, the drug discovery and development division of Scripps Research, was supported by funding from the Bill & Melinda Gates Foundation
Feedback and remarks of the industry and stakeholders are invited till the 25th of March 2022
It signals Cordis' renewed investment in innovation
Over the last 35 years, Dr. Moopen – Founder Chairman and Managing Director of Aster DM Healthcare has played a phenomenal role in strengthening the healthcare delivery system in GCC
As a part of its CSR initiatives, the ‘Healthcare Heroes of India’ Awards by Metropolis aims to identify and recognize those individuals and institutions in healthcare sector with a strong sense of purpose and commitment towards patient care and who have prioritized it over all other growth parameters
Commits to plant 5000 trees in phase 1 with its partner SankalpTaru Foundation
Dr. Bibikova is an international leader with over 25 years of experience in genomics industry
According to an Injury Surveillance Report by NCA last year, 14.75 % of players sustained shoulder injuries, 13.11% of players sustained knee injuries and almost 74 % players suffer from career-threatening Anterior Cruciate Ligament (ACL) injuries in the 1st two years of return to sport
12-week certificate course commences on March 10th 2022
Subscribe To Our Newsletter & Stay Updated
